CytoMed Therapeutics Net Worth
CytoMed Therapeutics Net Worth Breakdown | GDTC |
CytoMed Therapeutics Net Worth Analysis
CytoMed Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including CytoMed Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of CytoMed Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform CytoMed Therapeutics' net worth analysis. One common approach is to calculate CytoMed Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares CytoMed Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing CytoMed Therapeutics' net worth. This approach calculates the present value of CytoMed Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of CytoMed Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate CytoMed Therapeutics' net worth. This involves comparing CytoMed Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into CytoMed Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if CytoMed Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding CytoMed Therapeutics' net worth research are outlined below:
| CytoMed Therapeutics is way too risky over 90 days horizon | |
| CytoMed Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 290.56 K. Net Loss for the year was (3.13 M) with profit before overhead, payroll, taxes, and interest of 355.19 K. | |
| CytoMed Therapeutics generates negative cash flow from operations | |
| About 69.0% of the company shares are held by company insiders | |
| Latest headline from simplywall.st: CytoMed Therapeutics Leads 3 US Penny Stocks To Consider |
CytoMed Therapeutics Quarterly Good Will |
|
CytoMed Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in CytoMed Therapeutics Limited. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to CytoMed Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of May 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Follow CytoMed Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 26.17 M.Market Cap |
|
Project CytoMed Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.31) | |
| Return On Capital Employed | (0.29) | (0.30) | |
| Return On Assets | (0.29) | (0.31) | |
| Return On Equity | (0.42) | (0.45) |
When accessing CytoMed Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures CytoMed Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of CytoMed Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of CytoMed Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CytoMed Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CytoMed Therapeutics' management manipulating its earnings.
Evaluate CytoMed Therapeutics' management efficiency
CytoMed Therapeutics has return on total asset (ROA) of (0.1744) % which means that it has lost $0.1744 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2626) %, meaning that it created substantial loss on money invested by shareholders. CytoMed Therapeutics' management efficiency ratios could be used to measure how well CytoMed Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of January 7, 2025, Return On Tangible Assets is expected to decline to -0.31. In addition to that, Return On Capital Employed is expected to decline to -0.3. At present, CytoMed Therapeutics' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 12.2 M, whereas Net Tangible Assets are forecasted to decline to about 485.8 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.95 | 1.00 | |
| Net Current Asset Value | -1.8 M | -1.9 M | |
| Tangible Asset Value | 484.8 K | 460.6 K | |
| Tangible Book Value Per Share | 0.95 | 1.00 | |
| Enterprise Value Over EBITDA | (13.34) | (14.01) | |
| Price Book Value Ratio | 7.05 | 6.70 | |
| Enterprise Value Multiple | (13.34) | (14.01) | |
| Price Fair Value | 7.05 | 6.70 | |
| Enterprise Value | 39.2 M | 24.5 M |
Understanding the operational decisions made by CytoMed Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CytoMed Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on CytoMed Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CytoMed Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Choo Chee Kong over a year ago CytoMed Therapeutics exotic insider transaction detected |
CytoMed Therapeutics Corporate Filings
6K | 6th of January 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 24th of June 2024 Other Reports | ViewVerify | |
13A | 23rd of May 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 22nd of April 2024 Other Reports | ViewVerify |
CytoMed Therapeutics Earnings per Share Projection vs Actual
CytoMed Therapeutics Corporate Directors
| Jieming Zeng | Chief Director | Profile | |
| Tien Luk | Chief Director | Profile | |
| Jieming MD | Chief Director | Profile | |
| Wee Tan | COO Director | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in CytoMed Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytoMed Therapeutics. If investors know CytoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytoMed Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.22) | Revenue Per Share | Quarterly Revenue Growth (0.21) | Return On Assets | Return On Equity |
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytoMed Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.